Skip to content
MarketScale
‹ Back to IndustriesSciences

Laying Out the Landscape in Today’s Patient Monitoring

More and more hospital environments rely on continuous, high-quality data to support faster clinical decisions, but much of today’s patient monitoring still varies widely by unit, device, and workflow. This episode kicks off a five-part Health and Life Sciences at the Edge series exploring The Future of Patient Monitoring. Intel’s Kaeli Tully, Solutions Engineer…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Michelle Dawn Mooney · Continuous Patient MonitoringCritical CareEarly Patient Deterioration DetectionIcu Monitoring
Share

Key takeaways

01

More and more hospital environments rely on continuous, high-quality data to support faster clinical decisions, but much of today’s patient monitoring still varies widely by unit, device, and workflow.

02

This episode kicks off a five-part Health and Life Sciences at the Edge series exploring The Future of Patient Monitoring.

03

Intel’s Kaeli Tully, Solutions Engineer…

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Start free

More and more hospital environments rely on continuous, high-quality data to support faster clinical decisions, but much of today’s patient monitoring still varies widely by unit, device, and workflow. This episode kicks off a five-part Health and Life Sciences at the Edge series exploring The Future of Patient Monitoring. Intel’s Kaeli Tully, Solutions Engineer for Healthcare and Life Sciences, and Dr. Sanjay Subramanian, Critical Care Physician and CEO/Founder of Omnicure, speak with Michelle Dawn Mooney about what patient monitoring looks like on the front lines and what it will take to spot decline earlier across the hospital.

Dr. Subramanian frames monitoring as a continuum across care intensity, noting that “hospitals are sort of and have always existed in two segments… the low-intensity segment and the high-intensity, which is the intensive care units.” While most patients receive some level of vital signs monitoring, he explains that “the frequency with which that happens is highly variable,” even though deterioration can occur without warning. In his view, “all patients deserve probably continuous monitoring,” but the barrier is often cost and operational feasibility.

The conversation also highlights why monitoring matters most outside the ICU, especially when hospitals face crowding and staffing gaps. Dr. Subramanian emphasizes that critical care is strained by workforce realities, sharing that “most, I would say 80% of ICUs in the country, don’t have dedicated 24-7 staffing by board-certified intensive care physicians,” which accelerates interest in telecritical care and tele-ICU models. He describes how “ICU without walls” expands critical care beyond a fixed unit, recognizing that patients “deteriorate on the floors… in the emergency rooms, the operating theaters, and the PACUs.” The goal becomes extending expertise and visibility wherever patients are.

From an infrastructure perspective, the episode digs into the challenge of heterogeneous device ecosystems and inconsistent access to data streams. Dr. Subramanian notes that “it becomes easier if the technology stack is homogenous,” but many hospitals have “multiple devices of different ages” and cannot “reliably access the data from them.” Looking forward, he identifies a clear priority: “We need to solve for getting access to data reliably, continuously, and that’s high fidelity at scale,” and pair it with “the appropriate workflows to make that data actionable.”

Learn more about patient monitoring innovation by connecting with Kaeli Tully and Dr. Sanjay Subramanian on LinkedIn, or by visiting Omnicure and Intel Health and Life Sciences.

Subscribe to this channel on Apple Podcasts and Spotify to hear more from the Intel Network and Edge Solutions Group.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

MD

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Sciences Insights

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Eli Lilly are investing $750 million to expand KwikPen injectable device production at Resilience's Cincinnati-region manufacturing facility, expected to create 400 high-skilled jobs and reach full operations by early 2027. The partnership builds on their collaboration since 2023, which has already produced over 150 million doses of Lilly medications for the U.S. market.

  • 01$750 million investment to expand Resilience's Ohio manufacturing capacity for Eli Lilly's KwikPen injectable device production
  • 02400 new high-skilled jobs expected in Cincinnati region, with full operations by early 2027
  • 03Partnership has already produced over 150 million doses of Lilly medications for the U.S. market since 2023

Sep 14, 2026

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS Materials and Yokogawa ran an autonomous AI controller on a butadiene distillation column for 35 days and cut steam use 40%. It’s a real operations proof point. It also puts integration and governance gaps front and center.

  • 01A 35-day closed-loop run is a stronger autonomy proof point than a demo, it forces plants to prove handover, fallback, and KPIs over real feed and operating swings.
  • 02Steam reduction claims are compelling, but procurement and ops teams should pin vendors to baselines, operating envelopes, and how off-spec avoidance is measured.
  • 03Agentic AI is showing up as “work management” and “shift checklist” agents before it replaces control engineers, which shifts requirements toward clean, permissioned data access.

Sep 13, 2026

Novaspace sees 6,500+ Earth observation satellites by 2035, and value shifts to payload integration

Novaspace sees 6,500+ Earth observation satellites by 2035, and value shifts to payload integration

Novaspace forecasts more than 6,500 Earth observation satellites launching by 2035. It also projects $155.9 billion in manufacturing revenue, based on a SpaceNews-posted release dated Aug. 21, 2026. As defense-led demand shifts toward revisit rate and persistence, payload integration and fleet interoperability become the hard parts.

  • 01$155.9 billion is tied specifically to satellite manufacturing, not launch or ground, which should reshape how teams size supplier commitments and make-buy decisions.
  • 02Novaspace’s “skyscraper model” framing implies procurement power is shifting to payload integration, test capacity, and software-defined operations, even as the bus becomes more standardized.

Sep 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

MD
Michelle Dawn Mooney

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512